EUVIMEDEUVIMED entdecken
Open Access

Complications, Adverse Drug Events, High Costs, and Disparities in Multisystem Inflammatory Syndrome in Children vs COVID-19

William Encinosa, Kyung Moon, Jessica Figueroa, Youssef Elias

JAMA Network Open · 2023

DOI: 10.1001/jamanetworkopen.2022.44975 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2023. Verfasst von William Encinosa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Agency for Healthcare Research and Quality, Rockville, Maryland. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, COVID-19, Connective Tissue Diseases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Multisystem inflammatory syndrome in children (MIS-C) causes severe inflammation of multiple organ systems after SARS-CoV-2 infection. During the pandemic, surveillance reporting of MIS-C was voluntary, with likely underreporting. For a rare syndrome like MIS-C, numerous data are needed to explore the disease in greater detail.

Objective

To use large all-payer billing data and the new International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Clinical Modification ( ICD-10-CM ) code for MIS-C to compare outcomes across MIS-C and COVID-19 over all 4057 hospitals in 31 states. Design, Setting, and Participants A retrospective cross-sectional study of all COVID-19 and MIS-C hospitalizations in individuals younger than 21 years from 31 states was conducted, using Agency for Healthcare Research and Quality 2021 Healthcare Cost and Utilization Project data. Analyses were conducted from February 1 to October 20, 2022. Main Outcomes and Measures Fifty complications, adverse medication events, costs, and the Social Vulnerability Index.

Results

There were 4107 individuals with MIS-C (median age, 9 [IQR, 5-13] years; 2443 [59.5%] male; 1384 [38.1%] White) and 23 686 individuals with COVID-19 without MIS-C (median age, 15 [IQR, 5-18] years; 12 878 [54.4%] female; 4605 [44.1%] White), with 1.48 (95% CI, 1.35-1.62) MIS-C hospitalizations per 100 000 children per month, ranging from 0.97 hospitalizations per 100 children for White and 1.99 hospitalizations per 100 children for Black children. Outcomes worsened as the number of organ system dysfunctions increased from 2 to 8 organs. Deaths associated with MIS-C increased from less than 1% to 5.8% (95% CI, 3.3%-8.4%) and from less than 1% to 17.2% (95% CI, 11.7%-22.7%) for COVID-19 ( P = .001). Adverse medication events associated with MIS-C increased from 4.9% (95% CI, 3.8%-6.0%) to 17.8% (95% CI, 13.7%-22.0%) and from 1.2% (95% CI, 1.0%-1.3%) to 13.4% (95% CI, 8.4%-18.3%) for COVID-19. The median length of stay for MIS-C increased from 4 (IQR, 2-5) to 8 (IQR, 5-12) days and from 3 (IQR, 2-5) to 16 (IQR, 7-23) days for COVID-19. Median costs for MIS-C increased from $16 225 (IQR, $9244-$26 822) to $53 359 (IQR, $35 920-$86 882) and from $6474 (IQR, $3741-$12 103) to $98 643 (IQR, $30 675-$204 956) for COVID-19. The percentage of MIS-C cases that were in Black children doubled from 16.2% to 31.7% ( P = .001) as organ dysfunction increased, remaining unchanged with COVID-19. Hospital stays for MIS-C increased by 1 day ( P = .01) for Black patients compared with White patients, with Black patients moving from the bottom to top quartile of socioeconomic vulnerability, with no disparity with COVID-19. Conclusions and Relevance In this cross-sectional study, MIS-C was more common and severe than previously reported, with more racial disparities in outcomes than were seen in patients with COVID-19. The findings of this study suggest that relying on mean outcomes for MIS-C from past studies can be misleading, since outcomes and disparities varied widely with the number of multiorgan dysfunctions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Related Side Effects and Adverse ReactionsCOVID-19Connective Tissue DiseasesMaleRetrospective StudiesChildFemaleHumansCross-Sectional StudiesAdolescentSARS-CoV-2Systemic Inflammatory Response Syndrome

Autor:innen und Institutionen

  • Agency for Healthcare Research and Quality, Rockville, Maryland.
  • McCourt School of Public Health, Georgetown University, Washington, DC.
  • Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
  • Now with Bacteriology and Mycology Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • Johns Hopkins Carey Business School, Baltimore, Maryland.
  • Department of Vascular and Interventional Radiology, Carle Foundation Hospital, Carle Illinois College of Medicine, Urbana.

Zitieren

APA

Encinosa, W., Moon, K., Figueroa, J., & Elias, Y. (2023). Complications, Adverse Drug Events, High Costs, and Disparities in Multisystem Inflammatory Syndrome in Children vs COVID-19. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2022.44975

Vancouver

Encinosa W, Moon K, Figueroa J, Elias Y. Complications, Adverse Drug Events, High Costs, and Disparities in Multisystem Inflammatory Syndrome in Children vs COVID-19. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2022.44975

BibTeX
@article{Encinosa2023,
  author = {Encinosa, William and Moon, Kyung and Figueroa, Jessica and Elias, Youssef},
  title = {Complications, Adverse Drug Events, High Costs, and Disparities in Multisystem Inflammatory Syndrome in Children vs COVID-19},
  journal = {JAMA Network Open},
  year = {2023},
  doi = {10.1001/jamanetworkopen.2022.44975}
}
Kostenlos starten →